{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:39:32Z","timestamp":1793399972372,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a hepatic manifestation of metabolic syndrome, frequently occurring alongside type 2 diabetes (T2D), and it can present in varied phenotypes. This review provides a critical analysis of gut-adipose tissue-liver axis (GALA) dysregulation in MASLD pathogenesis, contextualizing the discussion within both established and emerging paradigms. The review elucidates how GALA dysregulation shapes the interplay between MASLD and T2D, emphasizing inter-organ crosstalk among the gut, liver, and adipose tissue, and highlighting the role of microbial metabolites, notably bile acids. The review further summarizes recent advances in stratifying MASLD into distinct clusters, examining intricate associations with cardiometabolic comorbidities, and critically evaluates novel therapeutic approaches targeting GALA modulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>MASLD can show heterogeneous phenotypes. It significantly increases the risk of developing new-onset T2D, and both conditions often coexist due to their shared pathophysiological basis in insulin resistance. The gut microbiota influences immune function and modulates host metabolism by regulating glucose tolerance and insulin sensitivity through a specific crosstalk between the gut, liver, and adipose tissue. The dysregulation of the GALA may be a mechanism underlying the interplay between MASLD and T2D, influencing IR and metabolic syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A thorough investigation of GALA's role in the physiopathogenesis of MASLD and T2D highlights its potential to distinguish specific MASLD clusters and to identify personalized therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s11892-026-01623-8","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:51:07Z","timestamp":1775893867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes"],"prefix":"10.1007","volume":"26","author":[{"given":"Susanna","family":"Longo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso Giovanni","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Fern\u00e1ndez-Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"1623_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"key":"1623_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic dysfunction\u2013Associated steatotic liver disease. N Engl J Med. 2025;393:683\u201398. https:\/\/doi.org\/10.1056\/NEJMra2412865.","journal-title":"N Engl J Med"},{"key":"1623_CR3","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care. 2025;48:1057\u201382. https:\/\/doi.org\/10.2337\/dci24-0094.","journal-title":"Diabetes Care"},{"key":"1623_CR4","doi-asserted-by":"publisher","first-page":"111891","DOI":"10.1016\/j.diabres.2024.111891","volume":"217","author":"R Mollace","year":"2024","unstructured":"Mollace R, Longo S, Nardin M, Tavernese A, Musolino V, Cardamone A, et al. Role of MASLD in CVD: a review of emerging treatment options. Diabetes Res Clin Pract. 2024;217:111891. https:\/\/doi.org\/10.1016\/j.diabres.2024.111891.","journal-title":"Diabetes Res Clin Pract"},{"key":"1623_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00592-023-02088-x","volume":"60","author":"S Longo","year":"2023","unstructured":"Longo S, Rizza S, Federici M. Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes. Acta Diabetol. 2023;60:1007\u201317. https:\/\/doi.org\/10.1007\/s00592-023-02088-x.","journal-title":"Acta Diabetol"},{"key":"1623_CR6","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3624\u201333. https:\/\/doi.org\/10.1038\/s41591-024-03283-1.","journal-title":"Nat Med"},{"key":"1623_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","volume":"83","author":"GR Steinberg","year":"2025","unstructured":"Steinberg GR, Valvano CM, De Nardo W, Watt MJ. Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms. J Hepatol. 2025;83:584\u201395. https:\/\/doi.org\/10.1016\/j.jhep.2025.02.033.","journal-title":"J Hepatol"},{"key":"1623_CR8","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol. 2023;79:1557\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.033.","journal-title":"J Hepatol"},{"key":"1623_CR9","doi-asserted-by":"publisher","first-page":"e7502","DOI":"10.7717\/peerj.7502","volume":"7","author":"N Hasan","year":"2019","unstructured":"Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ. 2019;7:e7502. https:\/\/doi.org\/10.7717\/peerj.7502.","journal-title":"PeerJ"},{"key":"1623_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.chom.2015.03.005","volume":"17","author":"CJ Kelly","year":"2015","unstructured":"Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17:662\u201371. https:\/\/doi.org\/10.1016\/j.chom.2015.03.005.","journal-title":"Cell Host Microbe"},{"key":"1623_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1152\/physrev.00045.2009","volume":"90","author":"I Sekirov","year":"2010","unstructured":"Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859\u2013904. https:\/\/doi.org\/10.1152\/physrev.00045.2009.","journal-title":"Physiol Rev"},{"key":"1623_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41575-023-00771-6","volume":"20","author":"O Pabst","year":"2023","unstructured":"Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T. Gut\u2013liver axis: barriers and functional circuits. Nat Rev Gastroenterol Hepatol. 2023;20:447\u201361. https:\/\/doi.org\/10.1038\/s41575-023-00771-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1623_CR13","doi-asserted-by":"publisher","first-page":"2000375","DOI":"10.1002\/mnfr.202000375","volume":"64","author":"Y Ni","year":"2020","unstructured":"Ni Y, Ni L, Zhuge F, Fu Z. The gut microbiota and its metabolites, novel targets for treating and preventing non\u2010alcoholic fatty liver disease. Mol Nutr Food Res. 2020;64:2000375. https:\/\/doi.org\/10.1002\/mnfr.202000375.","journal-title":"Mol Nutr Food Res"},{"key":"1623_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s40168-021-01093-y","volume":"9","author":"H Han","year":"2021","unstructured":"Han H, Yi B, Zhong R, Wang M, Zhang S, Ma J, et al. From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators. Microbiome. 2021;9:162. https:\/\/doi.org\/10.1186\/s40168-021-01093-y.","journal-title":"Microbiome"},{"key":"1623_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12938\/bmfh.2020-046","volume":"40","author":"COM Jasirwan","year":"2021","unstructured":"Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes\/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota, Food and Health. 2021;40:50\u20138. https:\/\/doi.org\/10.12938\/bmfh.2020-046.","journal-title":"Biosci Microbiota, Food and Health"},{"key":"1623_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cmet.2019.08.002","volume":"30","author":"R Loomba","year":"2019","unstructured":"Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2019;30:607. https:\/\/doi.org\/10.1016\/j.cmet.2019.08.002.","journal-title":"Cell Metab"},{"key":"1623_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/19490976.2019.1681861","volume":"11","author":"S Astbury","year":"2020","unstructured":"Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI, Valdes AM. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes. 2020;11:569\u201380. https:\/\/doi.org\/10.1080\/19490976.2019.1681861.","journal-title":"Gut Microbes"},{"key":"1623_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3350\/cmh.2024.0359","volume":"31","author":"CJ Pirola","year":"2025","unstructured":"Pirola CJ, Landa MS, Schuman M, Garc\u00eda SI, Salatino A, Sookoian S. Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments. Clin Mol Hepatol. 2025;31:179\u201395. https:\/\/doi.org\/10.3350\/cmh.2024.0359.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"1623_CR19","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s12325-017-0556-1","volume":"34","author":"S Ballestri","year":"2017","unstructured":"Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34(6):1291\u2013326. https:\/\/doi.org\/10.1007\/s12325-017-0556-1.","journal-title":"Adv Ther"},{"key":"1623_CR20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","volume":"71","author":"J Mouries","year":"2019","unstructured":"Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216\u201328. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.005.","journal-title":"J Hepatol"},{"key":"1623_CR21","doi-asserted-by":"publisher","first-page":"165767","DOI":"10.1016\/j.bbadis.2020.165767","volume":"1866","author":"S-J Leigh","year":"2020","unstructured":"Leigh S-J, Morris MJ. Diet, inflammation and the gut microbiome: Mechanisms for obesity-associated cognitive impairment. Biochimica et Biophysica Acta (BBA) - Mol Basis Dis. 2020;1866:165767. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165767.","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol Basis Dis"},{"key":"1623_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/gut.2005.071118","volume":"55","author":"K Tomita","year":"2006","unstructured":"Tomita K. Tumour necrosis factor signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415\u201324. https:\/\/doi.org\/10.1136\/gut.2005.071118.","journal-title":"Gut"},{"key":"1623_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3760\/cma.j.cn501113-20210430-00215","volume":"29","author":"L Shao","year":"2021","unstructured":"Shao L, Song Y, Shi JP. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis]. Zhonghua Gan Zang Bing Za Zhi. 2021;29:505\u20139. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20210430-00215.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"1623_CR24","doi-asserted-by":"publisher","first-page":"10186","DOI":"10.1074\/jbc.M117.796631","volume":"293","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto H, Takeuchi S, Kubota K, Kobayashi Y, Kozakai S, Ukai I, et al. Lipopolysaccharide (LPS)-binding protein stimulates CD14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1\u2013IKK\u03f5\u2013IRF3 axis activation. J Biol Chem. 2018;293:10186\u2013201. https:\/\/doi.org\/10.1074\/jbc.M117.796631.","journal-title":"J Biol Chem"},{"key":"1623_CR25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"key":"1623_CR26","doi-asserted-by":"publisher","first-page":"G433","DOI":"10.1152\/ajpgi.00163.2009","volume":"300","author":"T Csak","year":"2011","unstructured":"Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol-Gastrointest Liver Physiol. 2011;300:G433\u201341. https:\/\/doi.org\/10.1152\/ajpgi.00163.2009.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"1623_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1515\/hmbci-2015-0010","volume":"22","author":"G Lastra","year":"2015","unstructured":"Lastra G, Manrique C. Perivascular adipose tissue, inflammation and insulin resistance: link to vascular dysfunction and cardiovascular disease. Horm Mol Biol Clin Investig. 2015;22:19\u201326. https:\/\/doi.org\/10.1515\/hmbci-2015-0010.","journal-title":"Horm Mol Biol Clin Investig"},{"key":"1623_CR28","doi-asserted-by":"publisher","first-page":"e02481","DOI":"10.1128\/mBio.02481-14","volume":"6","author":"KA Romano","year":"2015","unstructured":"Romano KA, Vivas EI, Amador-Noguez D, Rey FE. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine- N -oxide. MBio. 2015;6:e02481-14. https:\/\/doi.org\/10.1128\/mBio.02481-14.","journal-title":"MBio"},{"key":"1623_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","volume":"68","author":"H Chu","year":"2019","unstructured":"Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68:359\u201370. https:\/\/doi.org\/10.1136\/gutjnl-2018-316307.","journal-title":"Gut"},{"key":"1623_CR30","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/metabo12121243","volume":"12","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Vordoni A, Kalaitzidis RG. Trimethylamine N-oxide levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolites. 2022;12:1243. https:\/\/doi.org\/10.3390\/metabo12121243.","journal-title":"Metabolites"},{"key":"1623_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.celrep.2017.06.039","volume":"20","author":"M-E Dumas","year":"2017","unstructured":"Dumas M-E, Rothwell AR, Hoyles L, Aranias T, Chilloux J, Calderari S, et al. Microbial-host Co-metabolites are prodromal markers predicting phenotypic heterogeneity in behavior, obesity, and impaired glucose tolerance. Cell Rep. 2017;20:136\u201348. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.039.","journal-title":"Cell Rep"},{"key":"1623_CR32","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","volume":"24","author":"L Hoyles","year":"2018","unstructured":"Hoyles L, Fern\u00e1ndez-Real J-M, Federici M, Serino M, Abbott J, Charpentier J, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018;24:1070\u201380. https:\/\/doi.org\/10.1038\/s41591-018-0061-3.","journal-title":"Nat Med"},{"key":"1623_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jnutbio.2010.07.009","volume":"22","author":"MAR Vinolo","year":"2011","unstructured":"Vinolo MAR, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. 2011;22:849\u201355. https:\/\/doi.org\/10.1016\/j.jnutbio.2010.07.009.","journal-title":"J Nutr Biochem"},{"key":"1623_CR34","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/2050640618804444","volume":"6","author":"M Rau","year":"2018","unstructured":"Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, et al. Fecal SCFAs and SCFA\u2010producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T\u2010cell activation and advanced disease. United Eur Gastroenterol J. 2018;6:1496\u2013507. https:\/\/doi.org\/10.1177\/2050640618804444.","journal-title":"United Eur Gastroenterol J"},{"key":"1623_CR35","doi-asserted-by":"publisher","first-page":"102165","DOI":"10.1016\/j.redox.2021.102165","volume":"47","author":"C Gonz\u00e1lez-Bosch","year":"2021","unstructured":"Gonz\u00e1lez-Bosch C, Boorman E, Zunszain PA, Mann GE. Short-chain fatty acids as modulators of redox signaling in health and disease. Redox Biol. 2021;47:102165. https:\/\/doi.org\/10.1016\/j.redox.2021.102165.","journal-title":"Redox Biol"},{"key":"1623_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1073\/pnas.0906112107","volume":"107","author":"T Bansal","year":"2010","unstructured":"Bansal T, Alaniz RC, Wood TK, Jayaraman A. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci U S A. 2010;107:228\u201333. https:\/\/doi.org\/10.1073\/pnas.0906112107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1623_CR37","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.celrep.2018.03.109","volume":"23","author":"S Krishnan","year":"2018","unstructured":"Krishnan S, Ding Y, Saedi N, Choi M, Sridharan GV, Sherr DH, et al. Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. Cell Rep. 2018;23:1099\u2013111. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.109.","journal-title":"Cell Rep"},{"key":"1623_CR38","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.3390\/nu11092062","volume":"11","author":"Y Ji","year":"2019","unstructured":"Ji Y, Gao Y, Chen H, Yin Y, Zhang W. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress. Nutrients. 2019;11:2062. https:\/\/doi.org\/10.3390\/nu11092062.","journal-title":"Nutrients"},{"key":"1623_CR39","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1002\/ctm2.634","volume":"11","author":"JS Yu","year":"2021","unstructured":"Yu JS, Youn GS, Choi J, Kim C, Kim BY, Yang S, et al. Lactobacillus lactis and Pediococcus pentosaceus \u2010driven reprogramming of gut microbiome and metabolome ameliorates the progression of non\u2010alcoholic fatty liver disease. Clin Trans Med. 2021;11:e634. https:\/\/doi.org\/10.1002\/ctm2.634.","journal-title":"Clin Trans Med"},{"key":"1623_CR40","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.2337\/diabetes.50.9.2094","volume":"50","author":"N Maeda","year":"2001","unstructured":"Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPAR\u03b3 ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094\u20139. https:\/\/doi.org\/10.2337\/diabetes.50.9.2094.","journal-title":"Diabetes"},{"key":"1623_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00010.2008","volume":"89","author":"P Lefebvre","year":"2009","unstructured":"Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147\u201391. https:\/\/doi.org\/10.1152\/physrev.00010.2008.","journal-title":"Physiol Rev"},{"key":"1623_CR42","doi-asserted-by":"publisher","first-page":"9588","DOI":"10.3390\/ijms23179588","volume":"23","author":"P Zhang","year":"2022","unstructured":"Zhang P. Influence of foods and nutrition on the gut microbiome and implications for intestinal health. IJMS. 2022;23:9588. https:\/\/doi.org\/10.3390\/ijms23179588.","journal-title":"IJMS"},{"key":"1623_CR43","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","volume":"67","author":"N Jiao","year":"2018","unstructured":"Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67:1881\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2017-314307.","journal-title":"Gut"},{"key":"1623_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.5604\/01.3001.0011.7378","volume":"17","author":"A Gottlieb","year":"2018","unstructured":"Gottlieb A, Bechmann L, Canbay A. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Ann Hepatol. 2018;17:341\u20132. https:\/\/doi.org\/10.5604\/01.3001.0011.7378.","journal-title":"Ann Hepatol"},{"issue":"4","key":"1623_CR45","doi-asserted-by":"publisher","first-page":"e1103","DOI":"10.1210\/clinem\/dgae341","volume":"110","author":"AW Potter","year":"2025","unstructured":"Potter AW, Chin GC, Looney DP, Friedl KE. Defining overweight and obesity by percent body fat instead of body mass index. J Clin Endocrinol Metab. 2025;110(4):e1103\u20137. https:\/\/doi.org\/10.1210\/clinem\/dgae341.","journal-title":"J Clin Endocrinol Metab"},{"key":"1623_CR46","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/biom13121692","volume":"13","author":"T Turpin","year":"2023","unstructured":"Turpin T, Thouvenot K, Gonthier M-P. Adipokines and bacterial metabolites: a pivotal molecular bridge linking obesity and gut microbiota dysbiosis to target. Biomolecules. 2023;13:1692. https:\/\/doi.org\/10.3390\/biom13121692.","journal-title":"Biomolecules"},{"key":"1623_CR47","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/biology12121471","volume":"12","author":"D Gabbia","year":"2023","unstructured":"Gabbia D, De Martin S. Targeting the adipose tissue\u2013liver\u2013gut microbiota crosstalk to cure MASLD. Biology. 2023;12:1471. https:\/\/doi.org\/10.3390\/biology12121471.","journal-title":"Biology"},{"key":"1623_CR48","doi-asserted-by":"publisher","unstructured":"Longo S, Zupo F, Menghini R, Fern\u00e1ndez-Real JM, Federici M (2025) Association between triglyceride glucose-body mass index and diabetic nephropathy and renal function decline in type 2 diabetes: evidence of stronger links in men and older adults. Acta Diabetol [Internet]. [cited 2025 Dec 19]; https:\/\/doi.org\/10.1007\/s00592-025-02605-0","DOI":"10.1007\/s00592-025-02605-0"},{"key":"1623_CR49","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.numecd.2019.11.016","volume":"30","author":"S Rizza","year":"2020","unstructured":"Rizza S, Rossini V, Cardellini M, Luzi A, Longo S, Piciucchi G, et al. Diabetes influences cancer risk in patients with increased carotid atherosclerosis burden. Nutr Metab Cardiovasc Dis. 2020;30:652\u20135. https:\/\/doi.org\/10.1016\/j.numecd.2019.11.016.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1623_CR50","doi-asserted-by":"publisher","first-page":"e000977","DOI":"10.1136\/lupus-2023-000977","volume":"10","author":"S Ferrigno","year":"2023","unstructured":"Ferrigno S, Conigliaro P, Rizza S, Longo S, Nesi C, Carlucci F, et al. Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE. Lupus Sci Med. 2023;10:e000977. https:\/\/doi.org\/10.1136\/lupus-2023-000977.","journal-title":"Lupus Sci Med"},{"key":"1623_CR51","doi-asserted-by":"publisher","unstructured":"Longo S, Menghini R, Federici M (2023) Gut microbiota and type 2 diabetes mellitus. In: Federici M, Menghini R (eds) Gut microbiome, microbial metabolites and cardiometabolic risk [Internet]. Cham: Springer International Publishing; [cited 2025 Oct 25]. pp 1\u201331. https:\/\/doi.org\/10.1007\/978-3-031-08115-6_8-1","DOI":"10.1007\/978-3-031-08115-6_8-1"},{"key":"1623_CR52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s13238-017-0436-0","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Ji X, Wang Q, Li JZ. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell. 2018;9:164\u201377. https:\/\/doi.org\/10.1007\/s13238-017-0436-0.","journal-title":"Protein Cell"},{"key":"1623_CR53","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/metabo14070366","volume":"14","author":"NG Vallianou","year":"2024","unstructured":"Vallianou NG, Kounatidis D, Psallida S, Vythoulkas-Biotis N, Adamou A, Zachariadou T, et al. NAFLD\/MASLD and the Gut\u2013Liver Axis: from pathogenesis to treatment options. Metabolites. 2024;14:366. https:\/\/doi.org\/10.3390\/metabo14070366.","journal-title":"Metabolites"},{"key":"1623_CR54","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","volume":"24","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24:631\u201350. https:\/\/doi.org\/10.1038\/s41573-025-01183-8.","journal-title":"Nat Rev Drug Discov"},{"key":"1623_CR55","doi-asserted-by":"publisher","first-page":"101090","DOI":"10.1016\/j.molmet.2020.101090","volume":"46","author":"LL Baggio","year":"2021","unstructured":"Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090. https:\/\/doi.org\/10.1016\/j.molmet.2020.101090.","journal-title":"Mol Metab"},{"key":"1623_CR56","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010.","journal-title":"Mol Metab"},{"key":"1623_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19:201\u201316. https:\/\/doi.org\/10.1038\/s41574-022-00783-3.","journal-title":"Nat Rev Endocrinol"},{"key":"1623_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins ( GIP and GLP \u20101) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab. 2021;23:5\u201329. https:\/\/doi.org\/10.1111\/dom.14496.","journal-title":"Diabetes Obes Metab"},{"key":"1623_CR59","doi-asserted-by":"publisher","first-page":"108622","DOI":"10.1016\/j.jnutbio.2021.108622","volume":"92","author":"RE Moreira J\u00fanior","year":"2021","unstructured":"Moreira J\u00fanior RE, De Carvalho LM, Dos Reis DC, Cassali GD, Faria AMC, Maioli TU, et al. Diet-induced obesity leads to alterations in behavior and gut microbiota composition in mice. J Nutr Biochem. 2021;92:108622. https:\/\/doi.org\/10.1016\/j.jnutbio.2021.108622.","journal-title":"J Nutr Biochem"},{"key":"1623_CR60","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41366-023-01341-1","volume":"47","author":"J Sun","year":"2023","unstructured":"Sun J, Germain A, Kaglan G, Servant F, Lelouvier B, Federici M, et al. The visceral adipose tissue bacterial microbiota provides a signature of obesity based on inferred metagenomic functions. Int J Obes. 2023;47:1008\u201322. https:\/\/doi.org\/10.1038\/s41366-023-01341-1.","journal-title":"Int J Obes"},{"key":"1623_CR61","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cmet.2014.07.006","volume":"20","author":"MT Khan","year":"2014","unstructured":"Khan MT, Nieuwdorp M, B\u00e4ckhed F. Microbial modulation of insulin sensitivity. Cell Metab. 2014;20:753\u201360. https:\/\/doi.org\/10.1016\/j.cmet.2014.07.006.","journal-title":"Cell Metab"},{"key":"1623_CR62","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.2337\/dc13-0451","volume":"36","author":"M Tr\u00f8seid","year":"2013","unstructured":"Tr\u00f8seid M, Nestvold TK, Rudi K, Thoresen H, Nielsen EW, Lappeg\u00e5rd KT. Plasma lipopolysaccharide is closely associated with glycemic control and abdominal obesity: evidence from bariatric surgery. Diabetes Care. 2013;36:3627\u201332. https:\/\/doi.org\/10.2337\/dc13-0451.","journal-title":"Diabetes Care"},{"key":"1623_CR63","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.2337\/db11-0004","volume":"60","author":"JD Schertzer","year":"2011","unstructured":"Schertzer JD, Tamrakar AK, Magalh\u00e3es JG, Pereira S, Bilan PJ, Fullerton MD, et al. NOD1 activators link innate immunity to insulin resistance. Diabetes. 2011;60:2206\u201315. https:\/\/doi.org\/10.2337\/db11-0004.","journal-title":"Diabetes"},{"key":"1623_CR64","doi-asserted-by":"publisher","first-page":"259","DOI":"10.15252\/emmm.201404169","volume":"7","author":"E Denou","year":"2015","unstructured":"Denou E, Lolm\u00e8de K, Garidou L, Pomie C, Chabo C, Lau TC, et al. Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. EMBO Mol Med. 2015;7:259\u201374. https:\/\/doi.org\/10.15252\/emmm.201404169.","journal-title":"EMBO Mol Med"},{"key":"1623_CR65","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fimmu.2020.00724","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang J, Wise L, Fukuchi K-I. TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer\u2019s disease. Front Immunol. 2020;11:724. https:\/\/doi.org\/10.3389\/fimmu.2020.00724.","journal-title":"Front Immunol"},{"key":"1623_CR66","doi-asserted-by":"publisher","first-page":"E272","DOI":"10.1152\/ajpendo.00053.2012","volume":"303","author":"MAR Vinolo","year":"2012","unstructured":"Vinolo MAR, Rodrigues HG, Festuccia WT, Crisma AR, Alves VS, Martins AR, et al. Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. Am J Physiol Endocrinol Metab. 2012;303:E272-282. https:\/\/doi.org\/10.1152\/ajpendo.00053.2012.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1623_CR67","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2362.2011.02590.x","volume":"42","author":"S Al-Lahham","year":"2012","unstructured":"Al-Lahham S, Roelofsen H, Rezaee F, Weening D, Hoek A, Vonk R, et al. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur J Clin Invest. 2012;42:357\u201364. https:\/\/doi.org\/10.1111\/j.1365-2362.2011.02590.x.","journal-title":"Eur J Clin Invest"},{"key":"1623_CR68","doi-asserted-by":"publisher","first-page":"46337","DOI":"10.1038\/srep46337","volume":"7","author":"VD de Mello","year":"2017","unstructured":"de Mello VD, Paananen J, Lindstr\u00f6m J, Lankinen MA, Shi L, Kuusisto J, et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the finnish diabetes prevention study. Sci Rep. 2017;7:46337. https:\/\/doi.org\/10.1038\/srep46337.","journal-title":"Sci Rep"},{"key":"1623_CR69","doi-asserted-by":"publisher","first-page":"E819","DOI":"10.1152\/ajpendo.00327.2023","volume":"326","author":"II Lazaridis","year":"2024","unstructured":"Lazaridis II, Bosch AJT, Keller L, Low AJY, Tamarelle J, Moser SO, et al. Metabolic outcomes in obese mice undergoing one-anastomosis gastric bypass (OAGB) with a long or a short biliopancreatic limb. Am J Physiol Endocrinol Metab. 2024;326:E819\u201331. https:\/\/doi.org\/10.1152\/ajpendo.00327.2023.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1623_CR70","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3390\/biom13121695","volume":"13","author":"D Lecis","year":"2023","unstructured":"Lecis D, Prandi FR, Barone L, Belli M, Sergi D, Longo S, et al. Beyond the cardiovascular effects of glucagon-like peptide-1 receptor agonists: body slimming and plaque stabilization. Are new statins born? Biomolecules. 2023;13:1695. https:\/\/doi.org\/10.3390\/biom13121695.","journal-title":"Biomolecules"},{"key":"1623_CR71","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.cmet.2021.07.007","volume":"33","author":"Q Wu","year":"2021","unstructured":"Wu Q, Liang X, Wang K, Lin J, Wang X, Wang P, et al. Intestinal hypoxia-inducible factor 2\u03b1 regulates lactate levels to shape the gut microbiome and alter thermogenesis. Cell Metab. 2021;33:1988-2003.e7. https:\/\/doi.org\/10.1016\/j.cmet.2021.07.007.","journal-title":"Cell Metab"},{"key":"1623_CR72","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.celrep.2017.05.077","volume":"19","author":"RC Schugar","year":"2017","unstructured":"Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, et al. The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue. Cell Rep. 2017;19:2451\u201361. https:\/\/doi.org\/10.1016\/j.celrep.2017.05.077.","journal-title":"Cell Rep"},{"issue":"18","key":"1623_CR73","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1042\/CS20257571","volume":"139","author":"WH Lee","year":"2025","unstructured":"Lee WH, Kipp ZA, Bates EA, Pauss SN, Martinez GJ, Hinds TD Jr. The physiology of MASLD: molecular pathways between liver and adipose tissues. Clin Sci (Lond). 2025;139(18):1015\u201346. https:\/\/doi.org\/10.1042\/CS20257571.","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"1623_CR74","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031.","volume":"71","author":"C Rosso","year":"2019","unstructured":"Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol. 2019;71(5):1012\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.031.","journal-title":"J Hepatol"},{"issue":"1","key":"1623_CR75","doi-asserted-by":"publisher","first-page":"7173","DOI":"10.1038\/s41467-024-51078-2","volume":"15","author":"L L'homme","year":"2024","unstructured":"L\u2019homme L, Sermikli BP, Haas JT, Fleury S, Quemener S, Guinot V, et al. Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH. Nat Commun. 2024;15(1):7173. https:\/\/doi.org\/10.1038\/s41467-024-51078-2.","journal-title":"Nat Commun"},{"key":"1623_CR76","doi-asserted-by":"publisher","first-page":"1667037","DOI":"10.3389\/fendo.2025.1667037","volume":"16","author":"Z Li","year":"2025","unstructured":"Li Z, Chu H, Yang L. White adipose tissue browning and peroxisome proliferator activated receptors in MASLD. Front Endocrinol (Lausanne). 2025;16:1667037. https:\/\/doi.org\/10.3389\/fendo.2025.1667037.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1623_CR77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/gutjnl-2024-332602","volume":"74","author":"A Castells-Nobau","year":"2025","unstructured":"Castells-Nobau A, Moreno-Navarrete JM, De La Vega-Correa L, Puig I, Federici M, Sun J, et al. Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism. Gut. 2025;74:229\u201345. https:\/\/doi.org\/10.1136\/gutjnl-2024-332602.","journal-title":"Gut"},{"key":"1623_CR78","doi-asserted-by":"publisher","first-page":"9196","DOI":"10.1038\/s41598-021-88493-0","volume":"11","author":"S Miyata","year":"2021","unstructured":"Miyata S, Kawashima Y, Sakai M, Matsubayashi M, Motoki K, Miyajima Y, et al. Discovery, optimization, and evaluation of non-bile acid FXR\/TGR5 dual agonists. Sci Rep. 2021;11:9196. https:\/\/doi.org\/10.1038\/s41598-021-88493-0.","journal-title":"Sci Rep"},{"key":"1623_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mce.2015.07.012","volume":"414","author":"MS Shihabudeen","year":"2015","unstructured":"Shihabudeen MS, Roy D, James J, Thirumurugan K. Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance. Mol Cell Endocrinol. 2015;414:19\u201328. https:\/\/doi.org\/10.1016\/j.mce.2015.07.012.","journal-title":"Mol Cell Endocrinol"},{"key":"1623_CR80","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.2337\/db13-0639","volume":"62","author":"RA Haeusler","year":"2013","unstructured":"Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12\u03b1-hydroxylated bile acids. Diabetes. 2013;62:4184\u201391. https:\/\/doi.org\/10.2337\/db13-0639.","journal-title":"Diabetes"},{"key":"1623_CR81","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","volume":"318","author":"JYL Chiang","year":"2020","unstructured":"Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol-Gastrointest Liver Physiol. 2020;318:G554\u201373. https:\/\/doi.org\/10.1152\/ajpgi.00223.2019.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"1623_CR82","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12915-017-0462-7","volume":"15","author":"X Zheng","year":"2017","unstructured":"Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, et al. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol. 2017;15:120. https:\/\/doi.org\/10.1186\/s12915-017-0462-7.","journal-title":"BMC Biol"},{"key":"1623_CR83","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1210\/clinem\/dgab531","volume":"106","author":"L Qi","year":"2021","unstructured":"Qi L, Tian Y, Chen Y. Circulating bile acid profiles: a need for further examination. J Clin Endocrinol Metab. 2021;106:3093\u2013112. https:\/\/doi.org\/10.1210\/clinem\/dgab531.","journal-title":"J Clin Endocrinol Metab"},{"key":"1623_CR84","doi-asserted-by":"publisher","first-page":"e0167319","DOI":"10.1371\/journal.pone.0167319","volume":"11","author":"K Govindarajan","year":"2016","unstructured":"Govindarajan K, MacSharry J, Casey PG, Shanahan F, Joyce SA, Gahan CGM. Unconjugated bile acids influence expression of circadian genes: a potential mechanism for microbe-host crosstalk. PLoS ONE. 2016;11:e0167319. https:\/\/doi.org\/10.1371\/journal.pone.0167319.","journal-title":"PLoS ONE"},{"key":"1623_CR85","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1210\/jc.2015-2583","volume":"101","author":"RA Haeusler","year":"2016","unstructured":"Haeusler RA, Camastra S, Nannipieri M, Astiarraga B, Castro-Perez J, Xie D, et al. Increased bile acid synthesis and impaired bile acid transport in human obesity. J Clin Endocrinol Metab. 2016;101:1935\u201344. https:\/\/doi.org\/10.1210\/jc.2015-2583.","journal-title":"J Clin Endocrinol Metab"},{"key":"1623_CR86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1753-0407.2009.00064.x","volume":"2","author":"M Bose","year":"2010","unstructured":"Bose M, Teixeira J, Olivan B, Bawa B, Arias S, Machineni S, et al. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010;2:47\u201355. https:\/\/doi.org\/10.1111\/j.1753-0407.2009.00064.x.","journal-title":"J Diabetes"},{"key":"1623_CR87","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41575-018-0057-y","volume":"15","author":"P Sinclair","year":"2018","unstructured":"Sinclair P, Brennan DJ, le Roux CW. Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. Nat Rev Gastroenterol Hepatol. 2018;15:606\u201324. https:\/\/doi.org\/10.1038\/s41575-018-0057-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1623_CR88","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.2337\/db10-0253","volume":"59","author":"J-P Furet","year":"2010","unstructured":"Furet J-P, Kong L-C, Tap J, Poitou C, Basdevant A, Bouillot J-L, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049\u201357. https:\/\/doi.org\/10.2337\/db10-0253.","journal-title":"Diabetes"},{"key":"1623_CR89","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/jam.13158","volume":"121","author":"M-Y Park","year":"2016","unstructured":"Park M-Y, Kim SJ, Ko EK, Ahn S-H, Seo H, Sung M-K. Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob\/ob mice. J Appl Microbiol. 2016;121:800\u201310. https:\/\/doi.org\/10.1111\/jam.13158.","journal-title":"J Appl Microbiol"},{"key":"1623_CR90","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s11695-015-1878-1","volume":"26","author":"AP Belgaumkar","year":"2016","unstructured":"Belgaumkar AP, Vincent RP, Carswell KA, Hughes RD, Alaghband-Zadeh J, Mitry RR, et al. Changes in bile acid profile after laparoscopic sleeve gastrectomy are associated with improvements in metabolic profile and fatty liver disease. OBES SURG. 2016;26:1195\u2013202. https:\/\/doi.org\/10.1007\/s11695-015-1878-1.","journal-title":"OBES SURG"},{"key":"1623_CR91","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/bjs.11208","volume":"106","author":"S Ahlin","year":"2019","unstructured":"Ahlin S, Cefalo C, Bondia-Pons I, Capristo E, Marini L, Gastaldelli A, et al. Bile acid changes after metabolic surgery are linked to improvement in insulin sensitivity. Br J Surg. 2019;106:1178\u201386. https:\/\/doi.org\/10.1002\/bjs.11208.","journal-title":"Br J Surg"},{"key":"1623_CR92","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/biomedicines12020264","volume":"12","author":"S Longo","year":"2024","unstructured":"Longo S, Del Chierico F, Scanu M, Toto F, Legramante JM, Rizza S, et al. An investigation of metabolic risk factors and gut microbiota in unexplained syncope. Biomedicines. 2024;12:264. https:\/\/doi.org\/10.3390\/biomedicines12020264.","journal-title":"Biomedicines"},{"key":"1623_CR93","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3390\/biomedicines12112641","volume":"12","author":"S Longo","year":"2024","unstructured":"Longo S, Cicalini I, Pieragostino D, De Laurenzi V, Legramante JM, Menghini R, et al. A metabolomic approach to unexplained syncope. Biomedicines. 2024;12:2641. https:\/\/doi.org\/10.3390\/biomedicines12112641.","journal-title":"Biomedicines"},{"key":"1623_CR94","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1210\/en.2012-2069","volume":"154","author":"R Kohli","year":"2013","unstructured":"Kohli R, Setchell KD, Kirby M, Myronovych A, Ryan KK, Ibrahim SH, et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology. 2013;154:2341\u201351. https:\/\/doi.org\/10.1210\/en.2012-2069.","journal-title":"Endocrinology"},{"key":"1623_CR95","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1210\/en.2011-2145","volume":"153","author":"DJ Pournaras","year":"2012","unstructured":"Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613\u20139. https:\/\/doi.org\/10.1210\/en.2011-2145.","journal-title":"Endocrinology"},{"key":"1623_CR96","doi-asserted-by":"publisher","first-page":"108032","DOI":"10.1016\/j.phrs.2025.108032","volume":"222","author":"S Longo","year":"2025","unstructured":"Longo S, Mollace R, Casagrande V, Bucciarelli L, Martelli E, Menghini R, et al. Glycometabolic cardiac dysfunction in HFpEF: Lessons from multi-omics studies. Pharmacol Res. 2025;222:108032. https:\/\/doi.org\/10.1016\/j.phrs.2025.108032.","journal-title":"Pharmacol Res"},{"key":"1623_CR97","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi O, De Vincentis A, Tavaglione F, Malvestiti F, Li-Gao R, Mancina RM, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3614\u201323. https:\/\/doi.org\/10.1038\/s41591-024-03284-0.","journal-title":"Nat Med"},{"key":"1623_CR98","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.cell.2020.02.016","volume":"180","author":"I Nemet","year":"2020","unstructured":"Nemet I, Saha PP, Gupta N, Zhu W, Romano KA, Skye SM, et al. A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors. Cell. 2020;180:862-877.e22. https:\/\/doi.org\/10.1016\/j.cell.2020.02.016.","journal-title":"Cell"},{"key":"1623_CR99","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1056\/NEJMe2504717","volume":"392","author":"TG Simon","year":"2025","unstructured":"Simon TG. Semaglutide for metabolic dysfunction\u2013associated steatohepatitis. N Engl J Med. 2025;392:2160\u20131. https:\/\/doi.org\/10.1056\/NEJMe2504717.","journal-title":"N Engl J Med"},{"key":"1623_CR100","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","volume":"392","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in compensated liver cirrhosis caused by MASH. N Engl J Med. 2025;392:2413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2502242.","journal-title":"N Engl J Med"},{"key":"1623_CR101","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"1623_CR102","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"key":"1623_CR103","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa2404881.","journal-title":"N Engl J Med"},{"key":"1623_CR104","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/metabo11010022","volume":"11","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites. 2020;11:22. https:\/\/doi.org\/10.3390\/metabo11010022.","journal-title":"Metabolites"},{"key":"1623_CR105","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735.","journal-title":"BMJ"},{"key":"1623_CR106","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1001\/jama.2024.1215","volume":"331","author":"TG Simon","year":"2024","unstructured":"Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, et al. Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial. JAMA. 2024;331:920. https:\/\/doi.org\/10.1001\/jama.2024.1215.","journal-title":"JAMA"},{"key":"1623_CR107","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"key":"1623_CR108","doi-asserted-by":"publisher","first-page":"16684","DOI":"10.3390\/ijms242316684","volume":"24","author":"M Yi","year":"2023","unstructured":"Yi M, Fasina OB, Li Y, Xiang L, Qi J. Mixture of peanut skin extract, geniposide, and isoquercitrin improves the hepatic lipid accumulation of mice via modification of gut microbiota homeostasis and the TLR4 and AMPK signaling pathways. Int J Mol Sci. 2023;24:16684. https:\/\/doi.org\/10.3390\/ijms242316684.","journal-title":"Int J Mol Sci"},{"key":"1623_CR109","doi-asserted-by":"publisher","first-page":"6280","DOI":"10.3390\/ijms25116280","volume":"25","author":"T Min","year":"2024","unstructured":"Min T, Qiu S, Bai Y, Cao H, Guo J, Su Z. Cilostazol attenuates hepatic steatosis and intestinal disorders in nonalcoholic fatty liver disease. Int J Mol Sci. 2024;25:6280. https:\/\/doi.org\/10.3390\/ijms25116280.","journal-title":"Int J Mol Sci"},{"key":"1623_CR110","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3390\/nu16121804","volume":"16","author":"KA Klag","year":"2024","unstructured":"Klag KA, Bell R, Jia X, Seguin A, Maschek JA, Bronner M, et al. Low-iron diet-induced fatty liver development is microbiota dependent and exacerbated by loss of the mitochondrial iron importer Mitoferrin2. Nutrients. 2024;16:1804. https:\/\/doi.org\/10.3390\/nu16121804.","journal-title":"Nutrients"},{"key":"1623_CR111","doi-asserted-by":"publisher","first-page":"101341","DOI":"10.1016\/j.xcrm.2023.101341","volume":"4","author":"S Quesada-V\u00e1zquez","year":"2023","unstructured":"Quesada-V\u00e1zquez S, Castells-Nobau A, Latorre J, Oliveras-Ca\u00f1ellas N, Puig-Parnau I, Tejera N, et al. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity. Cell Rep Med. 2023;4:101341. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101341.","journal-title":"Cell Rep Med"},{"key":"1623_CR112","doi-asserted-by":"publisher","first-page":"116582","DOI":"10.1016\/j.biopha.2024.116582","volume":"174","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xie C, Lei Y, Ye D, Wang L, Xiong F, et al. Theabrownin from Qingzhuan tea prevents high-fat diet-induced MASLD via regulating intestinal microbiota. Biomed Pharmacother. 2024;174:116582. https:\/\/doi.org\/10.1016\/j.biopha.2024.116582.","journal-title":"Biomed Pharmacother"},{"key":"1623_CR113","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3390\/antiox13060664","volume":"13","author":"R Rosas-Campos","year":"2024","unstructured":"Rosas-Campos R, Sandoval-Rodr\u00edguez AS, Rodr\u00edguez-Sanabria JS, Vazqu\u00e9z-Esqueda \u00c1O, Alfaro-Martinez CR, Escutia-Guti\u00e9rrez R, et al. A novel foodstuff mixture improves the gut\u2013liver axis in MASLD mice and the gut microbiota in overweight\/obese patients. Antioxidants. 2024;13:664. https:\/\/doi.org\/10.3390\/antiox13060664.","journal-title":"Antioxidants"},{"key":"1623_CR114","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3390\/nu16081173","volume":"16","author":"K Ka\u017amierczak-Siedlecka","year":"2024","unstructured":"Ka\u017amierczak-Siedlecka K, Maciejewska-Markiewicz D, Sykulski M, Gruszczy\u0144ska A, Herman-I\u017cycka J, Wyle\u017co\u0142 M, et al. Gut microbiome\u2014how does two-month consumption of fiber-enriched rolls change microbiome in patients suffering from MASLD? Nutrients. 2024;16:1173. https:\/\/doi.org\/10.3390\/nu16081173.","journal-title":"Nutrients"},{"key":"1623_CR115","doi-asserted-by":"publisher","first-page":"100987","DOI":"10.1016\/j.jhepr.2023.100987","volume":"6","author":"JW Jaeger","year":"2024","unstructured":"Jaeger JW, Brandt A, Gui W, Yergaliyev T, Hern\u00e1ndez-Arriaga A, Muthu MM, et al. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression. JHEP Rep. 2024;6:100987. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100987.","journal-title":"JHEP Rep"},{"key":"1623_CR116","doi-asserted-by":"publisher","first-page":"116942","DOI":"10.1016\/j.biopha.2024.116942","volume":"177","author":"D Qin","year":"2024","unstructured":"Qin D, Pan P, Lyu B, Chen W, Gao Y. Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis. Biomed Pharmacother. 2024;177:116942. https:\/\/doi.org\/10.1016\/j.biopha.2024.116942.","journal-title":"Biomed Pharmacother"},{"key":"1623_CR117","doi-asserted-by":"publisher","first-page":"122948","DOI":"10.1016\/j.lfs.2024.122948","volume":"354","author":"AA Santos","year":"2024","unstructured":"Santos AA, Duarte R, Duarte M, Arella F, Marques V, Roos S, et al. Impact of Lactobacillaceae supplementation on the multi-organ axis during MASLD. Life Sci. 2024;354:122948. https:\/\/doi.org\/10.1016\/j.lfs.2024.122948.","journal-title":"Life Sci"},{"key":"1623_CR118","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/19490976.2018.1534513","volume":"10","author":"DD Heeney","year":"2019","unstructured":"Heeney DD, Zhai Z, Bendiks Z, Barouei J, Martinic A, Slupsky C, et al. Lactobacillus plantarum bacteriocin is associated with intestinal and systemic improvements in diet-induced obese mice and maintains epithelial barrier integrity in vitro. Gut Microbes. 2019;10:382\u201397. https:\/\/doi.org\/10.1080\/19490976.2018.1534513.","journal-title":"Gut Microbes"},{"key":"1623_CR119","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3390\/nu16132010","volume":"16","author":"C Li","year":"2024","unstructured":"Li C, Liu Z, Wei W, Chen C, Zhang L, Wang Y, et al. Exploring the regulatory effect of LPJZ-658 on copper deficiency combined with sugar-induced MASLD in middle-aged mice based on multi-omics analysis. Nutrients. 2024;16:2010. https:\/\/doi.org\/10.3390\/nu16132010.","journal-title":"Nutrients"},{"key":"1623_CR120","doi-asserted-by":"publisher","first-page":"14668","DOI":"10.1038\/s41598-023-41160-y","volume":"13","author":"KJ Choi","year":"2023","unstructured":"Choi KJ, Yoon MY, Kim J-E, Yoon SS. Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance. Sci Rep. 2023;13:14668. https:\/\/doi.org\/10.1038\/s41598-023-41160-y.","journal-title":"Sci Rep"},{"key":"1623_CR121","doi-asserted-by":"publisher","first-page":"2309683","DOI":"10.1080\/19490976.2024.2309683","volume":"16","author":"S Jin","year":"2024","unstructured":"Jin S, Chen P, Yang J, Li D, Liu X, Zhang Y, et al. Phocaeicola vulgatus alleviates diet-induced metabolic dysfunction-associated steatotic liver disease progression by downregulating histone acetylation level via 3-HPAA. Gut Microbes. 2024;16:2309683. https:\/\/doi.org\/10.1080\/19490976.2024.2309683.","journal-title":"Gut Microbes"},{"key":"1623_CR122","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40360-023-00721-7","volume":"24","author":"M More","year":"2023","unstructured":"More M, Chatterjee S, Saha P, Bose D, Trivedi A, Roy S. Host microbiome associated low intestinal acetate correlates with progressive NLRP3-dependent hepatic-immunotoxicity in early life microcystin-LR exposure. BMC Pharmacol Toxicol. 2023;24:78. https:\/\/doi.org\/10.1186\/s40360-023-00721-7.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1623_CR123","doi-asserted-by":"publisher","first-page":"107207","DOI":"10.1016\/j.phrs.2024.107207","volume":"204","author":"M Ballanti","year":"2024","unstructured":"Ballanti M, Antonetti L, Mavilio M, Casagrande V, Moscatelli A, Pietrucci D, et al. Decreased circulating IPA levels identify subjects with metabolic comorbidities: a multi-omics study. Pharmacol Res. 2024;204:107207. https:\/\/doi.org\/10.1016\/j.phrs.2024.107207.","journal-title":"Pharmacol Res"},{"key":"1623_CR124","doi-asserted-by":"publisher","first-page":"2307568","DOI":"10.1080\/19490976.2024.2307568","volume":"16","author":"BH Min","year":"2024","unstructured":"Min BH, Devi S, Kwon GH, Gupta H, Jeong J-J, Sharma SP, et al. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Gut Microbes. 2024;16:2307568. https:\/\/doi.org\/10.1080\/19490976.2024.2307568.","journal-title":"Gut Microbes"},{"key":"1623_CR125","doi-asserted-by":"publisher","first-page":"G717","DOI":"10.1152\/ajpgi.00304.2019","volume":"318","author":"P Lundgren","year":"2020","unstructured":"Lundgren P, Thaiss CA. The microbiome-adipose tissue axis in systemic metabolism. Am J Physiol-Gastrointest Liver Physiol. 2020;318:G717\u201324. https:\/\/doi.org\/10.1152\/ajpgi.00304.2019.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"1623_CR126","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.cmet.2018.05.006","volume":"27","author":"F Cignarella","year":"2018","unstructured":"Cignarella F, Cantoni C, Ghezzi L, Salter A, Dorsett Y, Chen L, et al. Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota. Cell Metab. 2018;27:1222-1235.e6. https:\/\/doi.org\/10.1016\/j.cmet.2018.05.006.","journal-title":"Cell Metab"},{"key":"1623_CR127","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nm.4357","volume":"23","author":"A Worthmann","year":"2017","unstructured":"Worthmann A, John C, R\u00fchlemann MC, Baguhl M, Heinsen F-A, Schaltenberg N, et al. Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nat Med. 2017;23:839\u201349. https:\/\/doi.org\/10.1038\/nm.4357.","journal-title":"Nat Med"},{"key":"1623_CR128","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1073\/pnas.1219451110","volume":"110","author":"A Everard","year":"2013","unstructured":"Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110:9066\u201371. https:\/\/doi.org\/10.1073\/pnas.1219451110.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-026-01623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-026-01623-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-026-01623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:51:10Z","timestamp":1775893870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-026-01623-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1007\/s11892-026-01623-8","relation":{},"ISSN":["1539-0829"],"issn-type":[{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not report any studies involving human or animal participants conducted by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}